If a patient with Alzheimer’s disease was started on Donepezil prematurely and the initial cognitive concerns have resolved, should the medication be discontinued or continued?

Should Donepezil Be Discontinued If Started Prematurely and Cognitive Concerns Resolved?

If a patient was started on Donepezil for suspected Alzheimer's disease but the cognitive concerns have since resolved, you should discontinue the medication, as there is no evidence of benefit in patients without dementia, and continuing treatment exposes them to unnecessary adverse effects.

Clinical Reasoning

The decision to discontinue hinges on clarifying the underlying diagnosis:

Key Diagnostic Considerations

If cognitive concerns have truly "resolved," this suggests:

• The patient likely did not have Alzheimer's disease
• Symptoms may have been due to reversible causes (delirium, depression, medication effects, metabolic disturbances)
• The patient may have had mild cognitive impairment (MCI) that improved

Evidence shows donepezil has NO benefit in mild cognitive impairment - patients with MCI showed no clinically significant improvement, and any short-term reduction in conversion to AD disappeared by 36 months 1. This is critical because it demonstrates that even in patients with objective cognitive impairment (but not dementia), donepezil provides no meaningful benefit.

Guideline-Based Approach to Discontinuation

The 2020 Canadian Consensus Conference provides clear criteria for discontinuing cholinesterase inhibitors 2:

Discontinue if:

• No clinically meaningful benefit was observed at any time during treatment (improvement, stabilization, or decreased rate of decline)
• The medication was prescribed for conditions other than confirmed AD, Parkinson's disease dementia, Lewy body dementia, or vascular dementia
• Poor medication adherence precludes assessment of effectiveness

Risks of Continuing Unnecessary Treatment

Continuing donepezil in someone without dementia exposes them to:

• Gastrointestinal adverse effects (nausea 11%, diarrhea 10%, vomiting 5%, anorexia 4%) 3
• Cardiovascular risks (bradycardia, syncope)
• Other adverse effects (insomnia, muscle cramps, weight loss)
• Unnecessary healthcare costs

The FDA label clearly indicates donepezil is approved only for dementia due to Alzheimer's disease 3, not for subjective cognitive concerns or resolved symptoms.

Practical Implementation

Before Discontinuing:

1. Confirm the diagnosis was incorrect:

   • Review initial cognitive testing - was there objective impairment?
   • Reassess current cognitive function with standardized testing (MMSE, MoCA)
   • Evaluate for alternative explanations for initial symptoms
   • Document that symptoms have resolved

2. Discuss with patient/family:

   • Explain that donepezil only benefits confirmed Alzheimer's disease
   • Address concerns about symptom recurrence
   • Emphasize that continuing unnecessary medication carries risks

Discontinuation Method:

While most studies used abrupt discontinuation 4, you can discontinue donepezil abruptly - there is no evidence requiring tapering in patients without true dementia. The withdrawal syndrome described in case reports 5 occurred in patients with confirmed Alzheimer's disease, not in those without dementia.

Important Caveats

Monitor after discontinuation for 4-8 weeks to ensure symptoms do not recur. If cognitive decline reappears after stopping:

• This suggests the diagnosis may have been correct after all
• The apparent "resolution" may have been the drug's therapeutic effect
• Consider restarting and obtaining more definitive diagnostic workup (neuropsychological testing, biomarkers, imaging)

However, research shows that in patients with true Alzheimer's disease, discontinuing donepezil results in measurable cognitive decline within weeks to months 6, 4. If no decline occurs after stopping, this confirms the medication was unnecessary.

The evidence is clear: donepezil should only be continued in patients with confirmed dementia due to Alzheimer's disease (or other approved indications like Parkinson's disease dementia or Lewy body dementia) who demonstrate ongoing benefit from treatment 2.